Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to 49 years of age, inclusive.
Epistemonikos ID: 6f501fd7124adcc522a9653b4a71b5496d5e4686
First added on: Jul 19, 2022